Key result
Paricalcitol and enalapril similarly attenuated cardiac hypertrophy and downregulated myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in uremic rats.
Why the study?
Does paricalcitol or enalapril reduce cardiac hypertrophy and myocardial RAS/FGF expression in rats with 5/6 nephrectomy?
Does paricalcitol or enalapril reduce cardiac hypertrophy and myocardial RAS/FGF expression in rats with 5/6 nephrectomy?
Paricalcitol and enalapril similarly attenuate uremic cardiac hypertrophy and downregulate myocardial RAS and FGFR-1 expression in a rat model of uremia, despite different effects on blood pressure.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of paricalcitol benefit in uremic cardiomyopathy; leaves open translation to human CKD trials.
BACKGROUND: Vitamin D attenuates uremic cardiac hypertrophy, possibly by suppressing the myocardial renin-angiotensin system (RAS) and fibroblast growth factors (FGFs). We compared the suppression of cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes offered by the vitamin D analog paricalcitol (Pc) or the angiotensin-converting enzyme inhibitor enalapril (E) in experimental uremia. METHODS: Rats with 5/6 nephrectomy received Pc or E for 8 weeks. Renal function, systolic blood pressure, and cardiac hypertrophy were evaluated. Myocardial expression of RAS genes, brain natriuretic peptide (BNP), and FGF receptor-1 (FGFR-1) were determined using quantitative reverse-transcription (pRT)-PCR. RESULTS: Blood pressure, proteinuria, and serum creatinine were significantly higher in untreated uremic animals. Hypertension was significantly reduced by E but only modestly by Pc; however, cardiac hypertrophy in the untreated group was similarly attenuated by Pc or E. Upregulation of myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in untreated uremic animals was reduced similarly by Pc and E, while the angiotensin II type 1 receptor was downregulated only by E. CONCLUSIONS: Uremic cardiac hypertrophy is associated with activation of the myocardial RAS and the FGFR-1. Downregulation of these genes induced by Pc and E results in similar amelioration of left ventricular hypertrophy despite the different antihypertensive effects of these drugs.
No takes yet. Share an insight, caveat, or question.
Freundlich et al. (2013) studied Experimental uremia and cardiac hypertrophy. Paricalcitol or Enalapril vs. Untreated uremic animals was evaluated on Cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes. Paricalcitol and enalapril similarly attenuated cardiac hypertrophy and downregulated myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in uremic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: